Remicade, a biologic drug indicated to treat rheumatoid arthritis and other autoimmune disorders has been linked to thrombotic thrombocytopenic purpura or TTP, a life-threatening blood disorder that can result in severe organ damage and other adverse health consequences.
The nationwide law firm of Bernstein Liebhard LLP is investigating reports linking Remicade to TTP. If you or a loved one were diagnosed with TTP while being treated with Remicade, please contact our attorneys by calling (888) 994-5118.
Remicade (infliximab) is an intravenous biologic drug approved for the treatment of:
Remicade belongs to a drug class called TNF-blockers. Tumor necrosis factor-alpha (TNF-alpha) is a protein that helps the immune system to function. However, too much TNF-alpha can cause excess inflammation, resulting in rheumatoid arthritis and other autoimmune disorders.
TNF-blockers like Remicade bind to this protein, blocking its action.
According to the “Postmarketing Experience” section of its label, Remicade has been linked to post-approval reports of TTP, or thrombotic thrombocytopenic purpura.
This life-threatening blood disorder occurs when platelets become “sticky” and form clots in the small vessels of the body. These clots can block blood flow to the heart, lungs, kidneys and other vital organs, resulting in irreversible organ damage.
Because so many platelets are being used to form unnecessary clots, they will not be able to perform their normal function: clotting blood at the site of an injury. Thus, even minor injuries can become major bleeding events in people with TTP.
Without treatment, 95% of people with TTP will die. Patients being treated with Remicade should contact their doctor if they experience:
TTP associated with Remicade is treated via plasma exchange (aka plasmapheresis).
Glucocorticoids, vincristine, rituximab, and cyclosporine may also be used to treat TTP secondary to Remicade if plasma therapy has failed or if a patient experiences frequent recurrence.
If treatment is not effective, spleen removal may be necessary.
If you have questions about TTP and Remicade, our attorneys can help. Call (888) 994-5118 or fill out the form on this page to contact our office today.
Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.